Valneva SE surged over 30% in premarket trading

(Oct 18) Valneva shares jumped 30% in Paris trading after saying its coronavirus vaccine candidate outperformed AstraZeneca's in a Phase 3 study, which met both its co-primary endpoints. Valneva said its vaccine had a neutralizing antibody seroconversion rate above 95% and that it had a better tolerability profile.